SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

Rhea-AI Summary

SCYNEXIS, Inc. (NASDAQ: SCYX) has initiated an underwritten public offering of common stock and warrants, including pre-funded warrants. The underwriters may purchase up to an additional 15% of the offered shares within 30 days. This offering is subject to market conditions, and no guarantees are made regarding its completion or terms. Guggenheim Securities is the book-running manager. The offering is based on a shelf registration statement filed with the SEC, originally effective in January 2021. SCYNEXIS is known for its lead antifungal drug, ibrexafungerp, aimed at treating drug-resistant infections.

Positive

• SCYNEXIS is raising capital through an underwritten public offering, which can support future growth initiatives.
• The company has successfully launched its first commercial product, BREXAFEMME, with FDA approval.
• Ibrexafungerp is in late-stage clinical trials for treating serious fungal infections, potentially enhancing market presence.

Negative

• The offering of common stock may lead to shareholder dilution.
• Market conditions could affect the ability to complete the offering on favorable terms.

JERSEY CITY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock, including pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers. SCYNEXIS intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock and warrants offered in the public offering (including shares underlying the pre-funded warrants). All of the shares of common stock and warrants in the offering will be sold by SCYNEXIS. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Guggenheim Securities, LLC is serving as book-running manager for the offering.

A shelf registration statement relating to the securities being sold in this offering was filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 31, 2020, and was declared effective on January 8, 2021. The offering will be made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the proposed public offering may be obtained by contacting: Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, or by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME^® (ibrexafungerp tablets). The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. In addition, late-stage clinical investigation of ibrexafungerp for the prevention of recurrent Vulvovaginal Candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

Forward-Looking Statements

This announcement contains forward-looking statements, including statements relating to SCYNEXIS’s expectations regarding the proposed public offering. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. SCYNEXIS cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions, risks associated with the COVID-19 global pandemic, the satisfaction of customary closing conditions related to the public offering and the additional risks described in SCYNEXIS’s annual report on Form 10-K for the year ended December 31, 2021, the preliminary prospectus supplement relating to the proposed public offering and other filings with the SEC. There can be no assurance that SCYNEXIS will be able to complete the public offering on the anticipated terms, or at all. SCYNEXIS undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in SCYNEXIS’s expectations.

CONTACT: 
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com

FAQ

What is the purpose of SCYNEXIS's public offering?

SCYNEXIS aims to raise capital for future growth and development initiatives.

When did SCYNEXIS announce its public offering?

SCYNEXIS announced its public offering on April 21, 2022.

What are the terms regarding additional shares in the SCYNEXIS offering?

Underwriters have a 30-day option to purchase up to an additional 15% of the offered shares.

How does SCYNEXIS's public offering impact shareholders?

The offering may lead to dilution of existing shares for current shareholders.

Who is managing SCYNEXIS's public offering?

Guggenheim Securities is serving as the book-running manager for the offering.